With Revlimid sales down, BMS slashes 2023 revenue …
Jul 27, 2023 · BMS sliced its 2023 sales projection for blood cancer drug Revlimid by a whopping $1 billion and cut its overall revenue projection. Instead of a previous forecast of a 2% revenue increase for...
Other content from fiercepharma.comBristol Myers Squibb's Revlimid finally faces …
Mar 7, 2022 · Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma treatment. But now, BMS can no longer hold off generic...
Revlimid and 2025 Medicare | Int'l Myeloma Foundation
Dec 5, 2024 · People across the U.S. are experiencing significant difficulty finding Medicare Part D plans that include Revlimid on their 2025 formularies. The formulary is the list of drugs that …
BMS' cash cow Revlimid faces first generic rivals in US
Mar 8, 2022 · Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 …
Amid generic attack, BMS's Revlimid shows it can take a punch
Jul 27, 2022 · For now, BMS is sticking with its guidance for 2022 Revlimid sales to fall between $9 and $9.5 billion. Sales of the drug crescendoed at $12.8 billion last year. In fact, Revlimid's...
- bing.com › videosWatch full video
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, …
Feb 2, 2023 · Bristol Myers Squibb & Co (NYSE: BMY) said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the …
BMS reports 2% revenue loss in 2023 after Revlimid …
Feb 2, 2024 · The company saw a decrease in sales of Revlimid (lenalidomide) following the entry of generic versions after its patent loss in 2022. Revlimid generated $6bn in 2023, compared to $12.9bn in 2021 before the loss.
BMS feels the pain of Revlimid erosion, cutting forecasts
Jul 28, 2023 · The hardest hit in its second-quarter results update was to blood cancer therapy Revlimid (lenalidomide), which is now expected to make around $5.5 billion this year – fully $1 billion less than...
Dr Reddy's surges 4% on Nuvama upgrade to 'buy ... - Moneycontrol
1 day ago · Nuvama expect Dr Reddy's new launches--Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026. …
What’s after Revlimid for Dr Reddy’s, Cipla, and Sun …
Feb 20, 2024 · Frontline pharmaceutical majors Cipla, Sun Pharma and Dr Reddy’s have had bumper earnings over the last few quarters, thanks to the high-margin blockbuster cancer drug Revlimid.
- Some results have been removed
